Milea Timbergen

52 114 . Geurs F, Kok TC. Regression of a great abdominal desmoid tumor by interferon alpha. J Clin Gastroenterol. 1993;16(3):264-265. 115 . Ariën F, Aleman JM, Op De Beeck B, Tjalma WAA. Treatment of aggressive pelvic fibromatosis with interferon. Obstet Gynecol. 2015;126(6):1219-1221. 116 . Raguse JD, Gath HJ, Oettle H, Bier J. Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg. 2004;33(6):606-609. 117 . Leithner A, Schnack B, Katterschafka T, Wiltschke C, Amann G, Windhager R, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. Journal of Surgical Oncology. 2000;73(1):21-25. 118 . Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606-619. 119 . Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515-1527. 120 . Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804(3):433-439. 121 . Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007;12(2):104-107. 122 . Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27(41):5477-5485. 123 . Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer. 2010;103(4):482-485. 124 . Meazza C, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, et al. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. Cancer Med. 2016;5(6):1204-1213. 125 . Cates JMM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, et al. Signal transduction pathway analysis in fibromatosis: Receptor and nonreceptor tyrosine kinases. Hum Pathol. 2012;43(10):1711-1718. 126 . Kosela-Paterczyk H, Rutkowski P. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. Expert Rev Anticancer Ther. 2017;17(12):1107-1116. 127 . Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv267. 128 . Szucs Z, Messiou C, Wong HH, Hatcher H, Miah A, Zaidi S, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421-426. 129 . Agresta L, Kim H, Turpin BK, Nagarajan R, Plemmons A, Szabo S, et al. Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatr Blood Cancer. 2018;65(6):e26968. 130 . Italiano A. NCT01876082 - PAZOPANIB Efficacy and Tolerance in Desmoids Tumors (DESMOPAZ), ClinicalTrial.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01876082?term=NCT01876082&rank=1 2013 [ 131 . Hyo Song Kim. NCT03802084 - A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03802084?cond=desmoid+fibromatosis&rank=8 132 . Weiss AR. NCT01235030 - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01265030?term=NCT01265030&rank=1 133 . O’Sullivan Coyne G. NCT01981551 - Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01981551?term=NCT01981551&rank=1 134 . SpringWorksTherapeutics. NCT03785964 - Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi) ClinicalTrials.gv Available from: https://clinicaltrials.gov/ct2/show/NCT03785964?term=nirogacestat&rank=1 135 . Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630. 2